The unprecedented efficacy and good tolerability showed by FGFR inhibitors in clinical trials have fostered the approval of pemigatinib, infigratinib and futibatinib as second-line treatments in locally advanced or metastatic iCCA patients with FGFR2 fusion or rearrangements9–11. The gene discussed is FGFR2; the disease is infantile convulsions and choreoathetosis.